The Relative Cost-Effectiveness of Anticoagulants
Author:
- 7 June 2011
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 123 (22) , 2519-2521
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial FibrillationCirculation, 2011
- 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)Circulation, 2011
- Developing the Sentinel System — A National Resource for Evidence DevelopmentNew England Journal of Medicine, 2011
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2009
- Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatranThrombosis Research, 2009
- The Challenge of Rising Health Care Costs — A View from the Congressional Budget OfficeNew England Journal of Medicine, 2007
- Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial FibrillationStroke, 2006
- Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysisBMJ, 2006